May 10th 2024
While Moderna expects mRNA-1345 to be approved later this month, the company cites FDA administrative constraints as reason for delay.
April 30th 2024
Your daily dose of the clinical news you may have missed.
April 22nd 2024
Researchers found that the COVID-19 booster dose elicited a 71%-84% increase in the median anti-spike half-life over that of the primary series.
March 29th 2024
Investigators found vaccine uptake of 41% among unvaccinated individuals who were part of a messaging intervention in the emergency department.
March 19th 2024
The novel 21-valent pneumococcal vaccine remains on track for the FDA PDUFA date of June 17, 2024; Merck adds this new data to the body of positive evidence.
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of February 25, 2022
Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of February 24, 2022
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of February 23, 2022
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of February 22, 2022
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of February 21, 2022
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of February 18, 2022
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of February 17, 2022
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of February 16, 2022
Pediatric Vaccination Lost in the Shuffle During COVID-19: A Quiz
How did up-to-date pediatric routine vaccination rates fare during the COVID-19 pandemic compared to before?
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of February 15, 2022
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of February 14, 2022
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of February 11, 2022
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of February 10, 2022
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of February 9, 2022
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of February 8, 2022
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of February 7, 2022
What has COVID-19 Taught the US About Flu?
Vaccination against flu is the best protection from the infection according to 61% of US adults surveyed by NFID. How do the rest feel about the threat?
COVID-19 Hospitalization 23 Times Higher for Unvaccinated During Omicron Surge
The COVID-19 Omicron variant may cause milder disease than the Delta variant, but its rapid spread in Los Angeles County still singled out unvaccinated Angelinos.
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of February 3, 2022
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of February 2, 2022
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of February 1, 2022
FDA Approves Second COVID-19 Vaccine, Moderna's Spikevax
Acting FDA Commissioner Janet Woodcock, MD, hopes the approval will help motivate more Americans to get vaccinated.
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of January 31, 2022
Shingles Vaccination Significantly Reduced Dementia Risk in Large Retrospective Cohort Study
In persons who received both the HZV and Tdap vaccines, a significant 50% reduction in risk of dementia was seen, suggesting a nonspecific underlying association.
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of January 27, 2022
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of January 26, 2022
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of January 24, 2022
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of January 21, 2022
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of January 19, 2022
“Nocebo” Effect Accounted for Nearly Two-thirds of COVID-19 Vaccine Adverse Events in New Analysis
Findings highlight the importance of educating the public about the potential for nocebo responses to help reduce worries about COVID-19 vaccination.